Verici Dx, a developer of advanced diagnostic tests for organ transplant rejection, has announced plans to raise approximately £2.5 million through a share placing and subscription. The company, which is listed on the London Stock Exchange's AIM market, said the funds would be used to accelerate the commercial rollout of its kidney transplant risk assessment tests and support ongoing clinical studies.
The fundraising comes as Verici Dx seeks to expand adoption of its two lead products — Clarava and Tuteva — which are designed to predict the risk of transplant rejection and guide immunosuppression therapy. The tests analyse RNA biomarkers from blood samples, offering a non-invasive alternative to traditional kidney biopsies. The company believes the technology could improve patient outcomes and reduce NHS costs by enabling earlier intervention.
Shares in Verici Dx have been volatile since its IPO, reflecting the early-stage nature of the business and the long development timelines for diagnostic tests. The company has not yet reported significant revenues, but it has secured partnerships with several transplant centres in the UK and US. Analysts have noted that the market for non-invasive transplant diagnostics is growing, driven by the rising number of kidney transplants and a push towards personalised medicine.
For UK investors and pension holders with exposure to small-cap healthcare stocks, the fundraising highlights both the potential and the risks of investing in early-stage medical technology companies. While Verici Dx's tests could eventually capture a share of a multi-million-pound market, the company remains pre-profit and dependent on additional capital to fund its operations. The placing price has not yet been disclosed, but existing shareholders may face dilution.
The broader context is that the UK's transplant diagnostics sector is gaining attention as the NHS seeks to improve long-term graft survival rates and reduce the burden of chronic kidney disease. If Verici Dx succeeds in scaling its tests, it could offer significant savings for the health service and better quality of life for transplant recipients. However, the company still faces regulatory hurdles and competition from established diagnostic players.
Source: Verici Dx regulatory announcement